248 related articles for article (PubMed ID: 24349027)
1. In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia.
Jafari S; Huang XF; Andrews JL; Fernandez-Enright F
PLoS One; 2013; 8(12):e80979. PubMed ID: 24349027
[TBL] [Abstract][Full Text] [Related]
2. Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.
Shu Q; Hu G; Li M
J Psychopharmacol; 2014 Apr; 28(4):363-75. PubMed ID: 24257809
[TBL] [Abstract][Full Text] [Related]
3. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.
Crocq MA; Guillon MS; Bailey PE; Provost D
Eur Psychiatry; 2007 Oct; 22(7):453-4. PubMed ID: 17761403
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study.
Kahn RS; Kane JM; Correll CU; Arevalo C; Simmons A; Graham C; Yagoda S; Hu B; McDonnell D
J Clin Psychiatry; 2023 Mar; 84(3):. PubMed ID: 36946605
[No Abstract] [Full Text] [Related]
5. A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers.
Evers SS; van Vliet A; van Vugt B; Scheurink AJ; van Dijk G
Psychoneuroendocrinology; 2016 Apr; 66():101-10. PubMed ID: 26802597
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.
Martins PJ; Haas M; Obici S
Diabetes; 2010 Oct; 59(10):2418-25. PubMed ID: 20682682
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs.
Schmidt RH; Jokinen JD; Massey VL; Falkner KC; Shi X; Yin X; Zhang X; Beier JI; Arteel GE
J Pharmacol Exp Ther; 2013 Oct; 347(1):126-35. PubMed ID: 23926289
[TBL] [Abstract][Full Text] [Related]
8. Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.
Liebig M; Gossel M; Pratt J; Black M; Haschke G; Elvert R; Juretschke HP; Neumann-Haefelin C; Kramer W; Herling AW
Obesity (Silver Spring); 2010 Oct; 18(10):1952-8. PubMed ID: 20168311
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?
Faden J; Serdenes R; Citrome L
Expert Rev Neurother; 2022 May; 22(5):365-376. PubMed ID: 35354374
[TBL] [Abstract][Full Text] [Related]
10. Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.
Zhang C; Fang Y; Xu L
Schizophr Res; 2014 Nov; 159(2-3):376-84. PubMed ID: 25219486
[TBL] [Abstract][Full Text] [Related]
11. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
[TBL] [Abstract][Full Text] [Related]
12. Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.
Chou S; Jones S; Li M
Brain Res; 2015 Aug; 1618():122-35. PubMed ID: 26049127
[TBL] [Abstract][Full Text] [Related]
13. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia.
Lu ML; Chen CH; Kuo PT; Lin CH; Wu TH
Schizophr Res; 2018 Mar; 193():139-145. PubMed ID: 28720417
[TBL] [Abstract][Full Text] [Related]
14. Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.
Gao J; Li J; Lu X; Yang J
Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1011-1016. PubMed ID: 36016507
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
[TBL] [Abstract][Full Text] [Related]
16. The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats.
Porter JH; McCallum SE; Varvel SA; Vann RE
Psychopharmacology (Berl); 2000 Feb; 148(3):224-33. PubMed ID: 10755735
[TBL] [Abstract][Full Text] [Related]
17. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
Taveira TH; Wu WC; Tschibelu E; Borsook D; Simonson DC; Yamamoto R; Langleben DD; Swift R; Elman I
J Psychopharmacol; 2014 Apr; 28(4):395-400. PubMed ID: 24218048
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
19. Treatment with the atypical antipsychotic, olanzapine, prevents the expression of amphetamine-induced place conditioning in the rat.
Mechanic JA; Maynard BT; Holloway FA
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Feb; 27(1):43-54. PubMed ID: 12551725
[TBL] [Abstract][Full Text] [Related]
20. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
Wallingford NM; Sinnayah P; Bymaster FP; Gadde KM; Krishnan RK; McKinney AA; Landbloom RP; Tollefson GD; Cowley MA
Neuropsychopharmacology; 2008 Nov; 33(12):2922-33. PubMed ID: 18322467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
